Results 191 to 200 of about 277,288 (290)

Folinic Acid Prophylaxis and Dose Adjustments Enable Safe Treatment with Pemetrexed in Patients with Renal Impairment

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Pemetrexed is a cornerstone in chemo(immunotherapy) of non‐small cell lung cancer and mesothelioma; however, it is contraindicated in patients with renal impairment due to severe toxicity concerns. Therefore, a large proportion of patients is withheld from effective chemo(immunotherapy).
Nikki de Rouw   +18 more
wiley   +1 more source

Navigating the Real World: A Scoping Review of Structured Frameworks to Effectively Identify, Evaluate, and Select Real‐World Data Sources for Fit‐for‐Purpose Studies

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
The potential of real‐world data (RWD), particularly from patient registries, has been increasingly recognized over the last decade by academia, regulators, and health technology assessment (HTA) bodies for its role in assessing a product's effectiveness and supporting regulatory submissions.
Sonia Zebachi   +13 more
wiley   +1 more source

Model‐Informed Precision Dosing of Busulfan for Children and Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Critical Evaluation of Current PK Models and Dose Recommendations

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Busulfan is administered intravenously in conditioning regimens prior to allogeneic hematopoietic stem cell transplantation (HSCT), with model‐informed precision dosing (MIPD) targeting a 4‐day cumulative AUC of 80–100 mg*hour/L. Three pharmacokinetic (PK) models—Bognar, Langenhorst, and McCune—were evaluated using data with a minimum of 1 and a median
Rashudy F. Mahomedradja   +13 more
wiley   +1 more source

Subcortical gray matter volumes and 5-year dementia risk in individuals with subjective cognitive decline or mild cognitive impairment: A multi-cohort analysis. [PDF]

open access: yesAlzheimers Dement
Rosbergen MT   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy